Nasdaq Iceland has approved Alvotech S.A’s (“Alvotech”) request for admission to trading of its shares on the Nasdaq Iceland Main Market (“Main Market”). Alvotech’s shares will be admitted to trading...

Alvotech Société anonyme Registered office: 9, rue de Bitbourg, L-1273 Luxembourg R.C.S. Luxembourg: B258884

Hafrun Fridriksdottir, previously Executive VP and Head of Global R&D at Teva, will become Chief Operating Officer Mark Levick has decided to step down as Chief Executive Officer and Robert...

Alvotech S.A. (“Alvotech”) has submitted its application to Nasdaq Iceland for admission of its shares for trading on the Nasdaq Iceland Main Market under the ticker symbol “ALVO”. The application...

Existing senior bonds upsized by $70 million with additional investment from a consortium of institutional investorsAlvotech acquires the Reykjavik manufacturing facility, previously utilized...

Revenue for first nine months of 2022 increased to $59.2 million, compared to $2.0 million for the same period in 2021Discussions with U.S. FDA progressed regarding both biologic license applications...

Increases availability of cost-effective high-concentration low-volume adalimumab in AustraliaFirst approved biosimilar from the partnership with Cipla, which also includes four other biosimilar...

Alvotech will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02The switching study was conducted to investigate the pharmacokinetics,...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...

Alvotech (NASDAQ: ALVO), a global biotech specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will...